Boston, MA, 03/13/2014 – The year end report and corporate highlights of Regado Biosciences, Inc. (NASDAQ:RGDO) were announced today. RGDO, which is a biopharmaceutical company which focuses on the development of drug system has announced this report and is also reported to organize a webcast and conference call. This conference call will be aimed at discussing the results and the highlights of the company for the better future performance of the company. This conference call is decided to be held on March 13, 2014 at 8:30 a.m. EDT.
The year 2013 has been considered a remarkable one and a truly formative year for RGDO. The chief Executive Officer of RGDO boasted of Regado Biosciences, Inc. (NASDAQ:RGDO)’s performance in the year 2013. He emphasized on the results obtained by the REGULATE-PCI Phase-3 Clinical trial and also expected this trial to be potentially profitable for the company.
Financial summary, 2013
The financial results of the year 2013 suggested that the company has leapt forward a step in the past twelve months. The yearend cash equivalent, which was $14.8 million at the end of 2012, has been raised up to $30.7 million at the end of 2013. In addition to this, the company has gross proceeds of $20 million in common stocks. The net loss was calculated to be $34.4 million as compared to $13.1 million at the end of the year 2012.
Regado Biosciences, Inc. (NASDAQ:RGDO) highlighted some business points in the announcements which have been listed below:
- RGDO began trading on the NASDAQ Capital market and successfully completed IPO
- The board of directors strengthened
- The first patient enrolled in the clinical study of REG1
- The expansion of the executive leadership team
- Results of the additional phase published
- Extension of the patent portfolio for the protection of core technology format
REG2’s acceptance by the food and drug company of the U.S.